AZD9291 a novel EGFR-TKI that overcomes T790M-mediated resistance in NSCLC

Date 04 March 2015
Event 13th International Congress on Targeted Anticancer Therapies
Session Mutant-specific kinase inhibitors
Topics Anti-Cancer Agents & Biologic Therapy
Drug Development
Non-Small-Cell Lung Cancer, Metastatic
Presenter David Planchard